ALVO
Alvotech
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · IS
$5.87
+9.93%Sep 18, 2026, 09:43 UTC
Fuji Pharma obtained manufacturing and marketing approval in Japan for two biosimilar products, ustekinumab BS 130mg intravenous infusion and golimumab BS 50mg subcutaneous autoinjector.
Source:Sep 16, 2026, 12:28 UTC
Alvotech shares rose 5.58% to $5.30 in after-hours trading on September 16, 2026, ahead of an FDA review decision.
Source:Aug 21, 2026, 13:00 UTC
Alvotech announced a licensing and commercialization agreement with Lotus Pharmaceutical for its proposed biosimilars AVT34 (durvalumab) and AVT87 (emicizumab) in the U.S. and selected Asian markets.
Source:Aug 19, 2026, 20:30 UTC
Alvotech announced its financial results for the first half of 2026 and provided a business update on August 19, 2026.
Jul 29, 2026, 13:25 UTC
Alvotech announced that the FDA closed its inspection of its manufacturing facility in Reykjavik, Iceland, with a Voluntary Action Indicated classification.
Jul 1, 2026, 08:00 UTC
Alvotech secured a $75 million term loan facility by amending its existing credit agreement with GoldenTree Asset Management LP and other lenders.
Source:Jun 16, 2026, 03:50 UTC
Alvotech priced a public offering of 22,666,667 ordinary shares at $3.75 per share, raising $152 million.
Jun 8, 2026, 08:00 UTC
Alvotech announced that the FDA accepted for review its Biologics License Application for AVT16, a proposed interchangeable biosimilar to Entyvio.
Jun 5, 2026, 18:35 UTC
Alvotech resubmitted Biologics License Applications (BLAs) to the FDA for its biosimilar candidates AVT05 and AVT06.
Source: